Compounds > 8-oxocoptisine
Page last updated: 2024-12-10

8-oxocoptisine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

8-oxocoptisine: anti-ulcerative colitis agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5245667
CHEMBL ID3612189
SCHEMBL ID16168521
MeSH IDM000599408

Synonyms (16)

Synonym
SCHEMBL16168521
CHEMBL3612189 ,
19716-61-1
8-oxycoptisine
8-oxocoptisine
bdbm50131223
FT-0777687
MS-25070
5,7,17,19-tetraoxa-13-azahexacyclo[11.11.0.02,10.04,8.015,23.016,20]tetracosa-1(24),2,4(8),9,15(23),16(20),21-heptaen-14-one
E88595
AC-35042
DTXSID901317158
CS-0143435
HY-N8346
PD150673
AKOS040760162
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
X-box-binding protein 1Rattus norvegicus (Norway rat)EC50 (µMol)0.07990.07980.07990.0800AID1256197; AID1634948
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1245293Transactivation of XBP1 (unknown origin) transfected in rat IEC-6 cells at 10 uM after 48 hrs by dual luciferase reporter gene assay2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Synthesis and Structure-Activity Relationships of Quaternary Coptisine Derivatives as Potential Anti-ulcerative Colitis Agents.
AID1890609Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 24 hrs by MTT assay2022Bioorganic & medicinal chemistry, 04-15, Volume: 60Isolation, synthesis and bioactivity evaluation of isoquinoline alkaloids from Corydalis hendersonii Hemsl. against gastric cancer in vitro and in vivo.
AID1634947Activation of XBP1 in rat IEC-6 cells assessed as transcriptional activity at 10 uM measured after 48 hrs by dual luciferase reporter gene assay relative to con 22016Journal of natural products, Apr-22, Volume: 79, Issue:4
Synthesis and Structure-Activity Relationships of N-Dihydrocoptisine-8-ylidene Aromatic Amines and N-Dihydrocoptisine-8-ylidene Aliphatic Amides as Antiulcerative Colitis Agents Targeting XBP1.
AID1245296Anti-ulcerative colitis activity in DSS-induced acute C57Bl/6J mouse ulcerative colitis model2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Synthesis and Structure-Activity Relationships of Quaternary Coptisine Derivatives as Potential Anti-ulcerative Colitis Agents.
AID1634948Activation of XBP1 in rat IEC-6 cells assessed as transcriptional activity measured after 48 hrs by dual luciferase reporter gene assay2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Synthesis and Structure-Activity Relationships of N-Dihydrocoptisine-8-ylidene Aromatic Amines and N-Dihydrocoptisine-8-ylidene Aliphatic Amides as Antiulcerative Colitis Agents Targeting XBP1.
AID1890611Antiproliferative activity against human GES1 cells assessed as reduction in cell viability after 24 hrs by MTT assay2022Bioorganic & medicinal chemistry, 04-15, Volume: 60Isolation, synthesis and bioactivity evaluation of isoquinoline alkaloids from Corydalis hendersonii Hemsl. against gastric cancer in vitro and in vivo.
AID1890610Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability after 24 hrs by MTT assay2022Bioorganic & medicinal chemistry, 04-15, Volume: 60Isolation, synthesis and bioactivity evaluation of isoquinoline alkaloids from Corydalis hendersonii Hemsl. against gastric cancer in vitro and in vivo.
AID1256196Transactivation of XBP1 in rat IEC-6 cells at 10 uM after 48 hrs by dual luciferase reporter gene assay relative to con22015Journal of natural products, Oct-23, Volume: 78, Issue:10
Cembranoids from the Gum Resin of Boswellia carterii as Potential Antiulcerative Colitis Agents.
AID1256197Transactivation of XBP1 in rat IEC-6 cells after 48 hrs by dual luciferase reporter gene assay2015Journal of natural products, Oct-23, Volume: 78, Issue:10
Cembranoids from the Gum Resin of Boswellia carterii as Potential Antiulcerative Colitis Agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
berberine
[no description available]		2.110alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.4110nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
protopine
[no description available]		2.4110dibenzazecine alkaloidplant metabolite
sulfasalazine
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.		2.5220
(+-)stylopine
[no description available]		2.5920
coptisine
[no description available]		2.1310
coptisine
coptisine: RN given refers to parent cpd		7.110alkaloidmetabolite
allocryptopine
[no description available]		2.4110aromatic ether;
cyclic acetal;
cyclic ketone;
dibenzazecine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound
protoberberine
protoberberine: a benzyltetrahydroisoquinoline derivative that appears as an isoquinoline annelated (adjoined) with a naphthylene; the nitrogen is typically quarternary; nitidine is annelated differently; RN given refers to parent cpd		2.110
discretamine
(S)-scoulerine : A berberine alkaloid isolated from Corydalis saxicola.		2.4110berberine alkaloid;
organic heterotetracyclic compound		EC 5.99.1.2 (DNA topoisomerase) inhibitor;
plant metabolite
feruloyltyramine
feruloyltyramine: structure given in first source; isolated from Cannabis sativa seeds, roots, leaves, and resin; induces hypothermia and motor incoordination in mice; moupinamide is (E)-isomer		2.4110tyraminesmetabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Colitis Gravis
[description not available]		02.830
Acute Disease
Disease having a short and relatively severe course.		02.1110
Colitis, Ulcerative
Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.		02.830
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		02.1110
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.1110
Cancer of Stomach
[description not available]		02.4110
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.4110